Are guidelines on use of colony-stimulating factors in solid cancers flawed?

Internal Medicine Journal

Volumn 39, Issue 4, 2009, Pages 259-262

  Haines, I E ^a,b   Olver, I ^c  

^a CABRINI INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c CANCER COUNCIL AUSTRALIA   (Australia)

Author keywords

Clinical guideline; Colony stimulating factor; Independent overview

Indexed keywords

ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR; DOCETAXEL;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL PROTOCOL; DRUG DOSE REDUCTION; FEBRILE NEUTROPENIA; GERM CELL TUMOR; HEAD AND NECK CANCER; HUMAN; MEDICAL RESEARCH; MEDICAL SOCIETY; NONHODGKIN LYMPHOMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SOLID TUMOR;

ANTINEOPLASTIC AGENTS; DRUG COSTS; DRUG INDUSTRY; EVIDENCE-BASED MEDICINE; HEMATOPOIETIC CELL GROWTH FACTORS; HUMANS; META-ANALYSIS AS TOPIC; MOTIVATION; NEOPLASMS; NEUTROPENIA; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNNECESSARY PROCEDURES;

EID: 65349092793     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2009.01899.x     Document Type: Review

References (24)

1. Steinbrook R. Guidance for guidelines. N Engl J Med 2007 356 : 331 3.
2. Tanne JH. US Clinical Guidelines often influenced by Industry. BMJ 2007 334 : 171.
3. Tanne JH. Group asks US National Institutes of Health to reveal industry ties. BMJ 2007 334 : 115.
4. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducciet L et al. 2006 Update of Recommendations for the use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline. J Clin Oncol 2006 24 : 3187 205.
5. Bajorin DF, Nichols CR, Margolin KA, Bacik J, Richardson PG, Vogelzang NJ et al. Phase III trial of conventional-dose chemotherapy alone or with high-dose chemotherapy for metastatic germ cell (GCT) patients(pts): A Cooperative group trial by Memorial Sloan-Kettering Cancer Centre, ECOG, SWOG and CALGB. ASCO Meeting Abstracts Jun 20 2006: 4510 or Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 24, No 18S (June 20 Supplement), 2006; 4510.
6. Ozols RF, Herbst RS, Colson YL, Gralow J, Bonner J, Walter J, Curran WJ Jr. et al. Clinical Cancer Advances 2006: Major Research Advances in Cancer Treatments, Prevention and Screening - A Report from the American Society of Clinical Oncology. J Clin Oncol 2007 25 : 146 62.
7. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for Advanced Non-Hodgkin's Lymphoma. N Eng J Med 1993 328 : 1002 6.
8. Peters WP, Rosner GL, Vredenburgh JJ, Shpall EJ, Crump M, Richardson PG et al. Prospective, Randomised Comparison of High-Dose Chemotherapy With Stem-cell Support Versus Intermediate-Dose Chemotherapy After Surgery and Adjuvant Chemotherapy in Women With High-Risk Primary Breast Cancer: A Report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol 2005 23 : 2191 200.
9. Haines I, Bosl G, Pfister D, Spiro R, Gerold F, Sessions R et al. Very high-dose cisplatin with bleomycin infusion as initial treatment of advanced head and neck cancer. J Clin Oncol Oct 1 1987 5 : 1594 600.
10. Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL et al. First and subsequent use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: A multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005 23 : 1178 84.
11. Timmer-Bonte JN, Adang EM Smit HJ, Biesma B, Wilshut FA, Bootsma GP et al. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small cell lung cancer. J Clin Oncol 2006 24 : 2991 7.
12. Timmer-Bonte JNH, Adang EMM, Termeer E, Severens JL Tjan-Heijnan VCG. Modeling the Cost Effectiveness of Secondary Febrile Neutropenia Prophylaxis During Standard-Dose Chemotherapy. J Clin Oncol 2008 26 : 290 6.
13. Berghmans T, Paesmans M, Lafitta JJ, Mascaux C, Meert AP, Jacquy C, et al. Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factor in febrile neutropenic cancer patients: A systematic review of the literature with meta-analysis. Support Care Cancer 2002 10 : 181 8.
14. Clark OAC, Lyman GH, Castro AA, Clark LGO Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: A meta-analysis of randomized controlled trials. J Clin Oncol 2005 23 : 4198 214.
15. Papaldo P, Lopez M, Martolla P, Cortesi E, Antimi M, Terzoli E et al. Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. J Clin Oncol 2005 23 : 6908 18.
16. Toner GC, Shapiro JD, Laidlaw CR, Rischin D, Millward MJ, M Wolf M et al. Low-dose versus standard-dose Lenograstim Prophylaxis after chemotherapy: A Randomized Cross-over Comparison. J Clin Oncol 1998 16 : 3874 9.
17. Brownlee S. Overtreated: Why Too Much Medicine is Making us Sicker and Poorer. New York: Bloomsbury; 2007.
18. Kamerow D. What is wrong with US health care. BMJ 2008 336 : 99.
19. Nabhan C. It is follicular. So why CHOP? J Clin Oncol 2007 25 : 915 16.
20. Nabhan C. Thalidomide and Dexamethasone for Newly diagnosed Multiple Myeloma. Is this really the standard of care? J Clin Oncol 2006 24 : 2967 8.
21. Antonarakis ES, Blackford AL, Garrett-Mayer E Eisenberger MA. Survival in men with Nonmetastatic Prostate Cancer treated with Hormone Therapy: A Quantitative Systematic Review. J Clin Oncol 2007 25 : 4998 5008.
22. Miller IK, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer. N Engl J Med 2007 357 : 2666 76.
23. Haines IE. A Positive step forward but more needed to maximize cost-benefits of new generation cancer therapies. J Clin Oncol 2007 25 : 31e 32.
24. Nowak R. Cancer Drugs we can all afford. New Scientist : pp 8-9; 1 Dec, 2007.